SCHEMBL26232249

SCHEMBL26232249

CNc1nc2[nH]cc(C=O)c2c(=O)[nH]1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.35
TYMS P04818 4/20 0.35
XDH P47989 1/20 0.33
PDE2A O00408 1/20 0.32
CYP2A6 P11509 1/20 0.32
MTOR P42345 1/20 0.31
RICTOR Q6R327 1/20 0.31
RPTOR Q8N122 1/20 0.31
MAPKAP1 Q9BPZ7 1/20 0.31
MLST8 Q9BVC4 1/20 0.31
CSNK2A2 P19784 1/20 0.31
CSNK2B P67870 1/20 0.31
CSNK2A1 P68400 1/20 0.31
GRIA1 P42261 1/20 0.31
GRIA2 P42262 1/20 0.31
GRIA3 P42263 1/20 0.31
GRIA4 P48058 1/20 0.31
ADORA3 P0DMS8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26232177 0.80 TYMS (0.41) KMT2ATYMSGRIA1GRIA2GRIA3
SCHEMBL17652009 0.75 KMT2A (0.35) KMT2ATYMSCYP2A6
SCHEMBL19275108 0.71 XDH (0.38) XDH
SCHEMBL19275107 0.66 MPO (0.41) KMT2ATYMS
SCHEMBL18132314 0.66 KMT2A (0.35) KMT2ACYP2A6
SCHEMBL13215451 0.66 PDK2 (0.43) KMT2ACYP2A6
SCHEMBL19913251 0.66 LRRK2 (0.42) KMT2A
SCHEMBL28969 0.65 PDPK1 (0.41) TYMSXDHCSNK2A2CSNK2BCSNK2A1
SCHEMBL22788995 0.65 CHUK (0.38) KMT2ACYP2A6
SCHEMBL6311633 0.65 CHUK (0.41) KMT2ACYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807623-B2 Nucleic acid-binding photoprobes and uses thereof ARRAKIS THERAPEUTICS, INC. (US) 2023-11-07 US disclosed
US-20230312520-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF ARRAKIS THERAPEUTICS, INC. 2023-10-05 US disclosed
US-20230286987-A1 COMPOUNDS THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2023-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312520-A1 NUCLEIC ACID-BINDING PHOTOPROBES AND USES THEREOF NSUN3, NSUN2, TARBP1 KMT2A 2159/4885TYMS 719/4885XDH 2372/4885
US-20230286987-A1 COMPOUNDS HAX1, NHERF1, CXCR1 KMT2A 512/4885TYMS 4374/4885XDH 61/4885
US-11807623-B2 Nucleic acid-binding photoprobes and uses thereof NSUN3, NSUN2, TARBP1 KMT2A 2159/4885TYMS 719/4885XDH 2372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.